Nicholas James, M.D.

Nicholas James M.D.

Assistant Professor

Department: Department of Orthopaedic Surgery and Rehabilitation
Business Phone: (904) 244-5946
Business Email:

Clinical Profile

  • Hand Surgery
  • Orthopaedic Surgery


Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
The Lancet. Oncology.23(5):650-658[DOI] 10.1016/S1470-2045(22)00158-9.[PMID] 35421369.
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
European urology.82(3):273-279[DOI] 10.1016/j.eururo.2022.04.017.[PMID] 35577644.
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
European urology.82(1):e18-e19[DOI] 10.1016/j.eururo.2022.04.004.[PMID] 35440417.
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.
European urology oncology.5(4):377-387[DOI] 10.1016/j.euo.2022.04.009.[PMID] 35641398.
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
European urology oncology.5(1):70-83[DOI] 10.1016/j.euo.2021.07.001.[PMID] 34353775.
Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
European urology oncology.():-[DOI] 10.1016/j.euo.2022.03.005.[PMID] 35410825.
Sagittal Band Injury and Extensor Tendon Realignment.
The Orthopedic clinics of North America.53(3):319-325[DOI] 10.1016/j.ocl.2022.02.004.[PMID] 35725040.
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
European urology.82(1):6-11[DOI] 10.1016/j.eururo.2022.02.010.[PMID] 35393158.
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA oncology.7(4):555-563[DOI] 10.1001/jamaoncol.2020.7857.[PMID] 33599706.
Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
European urology.80(1):12-15[DOI] 10.1016/j.eururo.2021.02.021.[PMID] 33653635.
Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
European urology.79(2):307-315[DOI] 10.1016/j.eururo.2020.11.036.[PMID] 33293079.
Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
European urology.80(2):e51-e52[DOI] 10.1016/j.eururo.2021.05.009.[PMID] 34053780.
Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
European urology.80(1):18-19[DOI] 10.1016/j.eururo.2021.04.034.[PMID] 33972095.
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
ESMO open.6(3):100152-[DOI] 10.1016/j.esmoop.2021.100152.[PMID] 33984672.
Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
European urology.80(4):522-523[DOI] 10.1016/j.eururo.2021.06.023.[PMID] 34274134.
Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review.
Clinical oncology (Royal College of Radiologists (Great Britain)).32(6):347-353[DOI] 10.1016/j.clon.2020.04.005.[PMID] 32389318.
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250].
European urology.78(1):e48-e50[DOI] 10.1016/j.eururo.2020.03.017.[PMID] 32446863.
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Annals of oncology : official journal of the European Society for Medical Oncology.31(3):442-[DOI] 10.1016/j.annonc.2020.01.002.[PMID] 32067690.
Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015.
European urology oncology.3(6):773-779[DOI] 10.1016/j.euo.2018.12.008.[PMID] 31411979.
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.
European urology.77(2):223-250[DOI] 10.1016/j.eururo.2019.09.035.[PMID] 31753752.
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO precision oncology.4():882-897[DOI] 10.1200/PO.19.00388.[PMID] 35050761.
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.
Journal of bone oncology.25():100311-[DOI] 10.1016/j.jbo.2020.100311.[PMID] 32995252.
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
JAMA oncology.6(2):206-216[DOI] 10.1001/jamaoncol.2019.4097.[PMID] 31830233.
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
European urology.77(2):260-268[DOI] 10.1016/j.eururo.2019.11.001.[PMID] 31843338.
Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8.
European urology.77(6):e156-e157[DOI] 10.1016/j.eururo.2020.02.013.[PMID] 32169314.
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
European urology oncology.3(4):412-419[DOI] 10.1016/j.euo.2020.05.003.[PMID] 32591246.
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Lancet (London, England).396(10260):1413-1421[DOI] 10.1016/S0140-6736(20)31553-1.[PMID] 33002429.
A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.
European urology oncology.2(3):294-301[DOI] 10.1016/j.euo.2019.02.001.[PMID] 31200844.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
European urology.76(6):719-728[DOI] 10.1016/j.eururo.2019.08.006.[PMID] 31447077.
Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Trials.20(1):294-[DOI] 10.1186/s13063-019-3322-7.[PMID] 31138292.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Annals of oncology : official journal of the European Society for Medical Oncology.30(12):e3-[DOI] .[PMID] 27141017.
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
International journal of radiation oncology, biology, physics.104(4):809-818[DOI] 10.1016/j.ijrobp.2019.03.015.[PMID] 30885775.
Muscarinic receptors regulate auditory and prefrontal cortical communication during auditory processing.
Neuropharmacology.144():155-171[DOI] 10.1016/j.neuropharm.2018.10.027.[PMID] 30352212.
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
European urology.76(1):73-81[DOI] 10.1016/j.eururo.2019.03.015.[PMID] 30910346.
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
European urology.76(1):115-124[DOI] 10.1016/j.eururo.2019.02.003.[PMID] 30826218.
Radiotherapy for metastatic prostate cancer-Authors' reply.
Lancet (London, England).394(10201):830-[DOI] 10.1016/S0140-6736(19)31829-X.[PMID] 31498099.
The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
European urology.75(3):e51-e52[DOI] 10.1016/j.eururo.2018.11.003.[PMID] 30454914.
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Trials.20(1):264-[DOI] 10.1186/s13063-019-3216-8.[PMID] 31138317.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
European urology oncology.1(6):449-458[DOI] 10.1016/j.euo.2018.06.004.[PMID] 31158087.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet (London, England).392(10162):2353-2366[DOI] 10.1016/S0140-6736(18)32486-3.[PMID] 30355464.
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
European urology.73(3):427-435[DOI] 10.1016/j.eururo.2017.06.021.[PMID] 28705540.
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology.29(5):1249-1257[DOI] 10.1093/annonc/mdy071.[PMID] 29788164.
'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.
Annals of oncology : official journal of the European Society for Medical Oncology.28(10):2327-2330[DOI] 10.1093/annonc/mdx410.[PMID] 28961849.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
The New England journal of medicine.377(4):338-351[DOI] 10.1056/NEJMoa1702900.[PMID] 28578639.
Abiraterone in Metastatic Prostate Cancer.
The New England journal of medicine.377(17):1696-7[DOI] 10.1056/NEJMc1711029.[PMID] 29069563.
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
European journal of cancer (Oxford, England : 1990).84():88-101[DOI] 10.1016/j.ejca.2017.07.003.[PMID] 28800492.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
BJU international.119(4):522-529[DOI] 10.1111/bju.13549.[PMID] 27256016.
Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.
European urology.72(1):e17-[DOI] 10.1016/j.eururo.2016.09.036.[PMID] 27720530.
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
European urology focus.3(6):606-614[DOI] 10.1016/j.euf.2017.01.010.[PMID] 28753849.
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
Clinical trials (London, England).14(5):451-461[DOI] 10.1177/1740774517725697.[PMID] 28830236.
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
The Lancet. Oncology.17(2):243-256[DOI] 10.1016/S1470-2045(15)00489-1.[PMID] 26718929.
Cancer Drugs Fund requires further reform.
BMJ (Clinical research ed.).354():i5090-[DOI] 10.1136/bmj.i5090.[PMID] 27677636.
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
JAMA oncology.2(4):493-9[DOI] 10.1001/jamaoncol.2015.5570.[PMID] 26794729.
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
JAMA oncology.2(3):348-57[DOI] 10.1001/jamaoncol.2015.4350.[PMID] 26606329.
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.34(22):2636-43[DOI] 10.1200/JCO.2016.66.9697.[PMID] 27298414.
Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.
Clinical oncology (Royal College of Radiologists (Great Britain)).28(10):666-7[DOI] 10.1016/j.clon.2016.07.004.[PMID] 27477123.
STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.
Lancet (London, England).388(10041):235-6[DOI] 10.1016/S0140-6736(16)31041-8.[PMID] 27479566.
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Health technology assessment (Winchester, England).20(53):1-288[DOI] 10.3310/hta20530.[PMID] 27434595.
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.
European urology.67(5):904-12[DOI] 10.1016/j.eururo.2014.08.076.[PMID] 25218582.
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
BJU international.116(6):880-7[DOI] 10.1111/bju.13069.[PMID] 25639506.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Annals of oncology : official journal of the European Society for Medical Oncology.26(8):1589-604[DOI] 10.1093/annonc/mdv257.[PMID] 26041764.
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
European urology.67(6):1028-1038[DOI] 10.1016/j.eururo.2014.09.032.[PMID] 25301760.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
BJU international.113(5b):E137-43[DOI] 10.1111/bju.12564.[PMID] 24219029.
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
The Lancet. Oncology.15(9):975-85[DOI] 10.1016/S1470-2045(14)70240-2.[PMID] 24974051.
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?
BJU international.113(2):189-99[DOI] 10.1111/bju.12469.[PMID] 24112742.
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
European urology.66(5):799-802[DOI] 10.1016/j.eururo.2014.05.038.[PMID] 24985962.
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
European urology.66(1):120-37[DOI] 10.1016/j.eururo.2014.02.038.[PMID] 24613684.
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
The Lancet. Oncology.15(7):738-46[DOI] 10.1016/S1470-2045(14)70183-4.[PMID] 24836273.
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Investigational new drugs.32(5):995-1004[DOI] 10.1007/s10637-014-0101-x.[PMID] 24771350.
Alpha emitter radium-223 and survival in metastatic prostate cancer.
The New England journal of medicine.369(3):213-23[DOI] 10.1056/NEJMoa1213755.[PMID] 23863050.
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial.
Clinical oncology (Royal College of Radiologists (Great Britain)).25(5):318-20[DOI] 10.1016/j.clon.2013.01.005.[PMID] 23489869.
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.
BJU international.111(5):697-9[DOI] 10.1111/bju.12087.[PMID] 23578233.
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
European urology.63(4):717-23[DOI] 10.1016/j.eururo.2012.11.042.[PMID] 23206856.
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
The Lancet. Oncology.13(5):549-58[DOI] 10.1016/S1470-2045(12)70088-8.[PMID] 22452894.
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
Trials.13():168-[DOI] 10.1186/1745-6215-13-168.[PMID] 22978443.
Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: a randomized controlled trial for men with prostate cancer.
International journal of urology : official journal of the Japanese Urological Association.18(8):553-4[DOI] 10.1111/j.1442-2042.2011.02783.x.[PMID] 21615523.
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
BJU international.106(7):966-73[DOI] 10.1111/j.1464-410X.2010.09638.x.[PMID] 20840318.
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Trials.10():39-[DOI] 10.1186/1745-6215-10-39.[PMID] 19519885.
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.27(32):5431-8[DOI] 10.1200/JCO.2008.20.1228.[PMID] 19805692.
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
European urology.55(5):1112-23[DOI] 10.1016/j.eururo.2008.11.002.[PMID] 19042080.
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
BJU international.103(4):464-9[DOI] 10.1111/j.1464-410X.2008.08034.x.[PMID] 18990168.
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.
Critical reviews in oncology/hematology.68 Suppl 1():S9-S22[DOI] 10.1016/j.critrevonc.2008.07.019.[PMID] 18723368.
Speeding up the evaluation of new agents in cancer.
Journal of the National Cancer Institute.100(17):1204-14[DOI] 10.1093/jnci/djn267.[PMID] 18728279.
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Clinical oncology (Royal College of Radiologists (Great Britain)).20(8):577-81[DOI] 10.1016/j.clon.2008.07.002.[PMID] 18760574.
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Journal of the National Cancer Institute.99(10):765-76[DOI] .[PMID] 17505072.
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Prostate cancer and prostatic diseases.9(3):221-9[DOI] .[PMID] 16801939.
Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study.
Clinical oncology (Royal College of Radiologists (Great Britain)).17(4):217-8[DOI] .[PMID] 15997913.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
The New England journal of medicine.351(15):1502-12[DOI] .[PMID] 15470213.
Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer.
European urology.38(3):279-86[DOI] .[PMID] 10940701.

Office Information

Academic Office
2nd Floor, Ambulatory Care Center
655 West 8th Street
Jacksonville, FL 32209
(904) 244-5946
Administrative Manager
Lisa Hernandez
(904) 244-5946


Medical Degree
2016 · University of South Florida, Tampa, FL, USA
Orthopaedic Surgery Residency
2021 · University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
Hand Surgery Fellowship
2022 · University of Tennessee College of Medicine, Memphis, TN, USA